On April 1, 2015 Merck's new HPV vaccine, Gardasil 9, was approved for use in Canada. Gardasil 9 targets HPV types 16, 18, 9, 11, 31, 33, 45, 52 and 58.


It should be noted that any reference to HPV testing in this document is specifically referring to high-risk HPV infection, as detected by current tests. HPV types classified as ‘high-risk’ include 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68.


52 Alternate terminology includes Pap or Papanicolaou smear, cervical smear, cervical/vaginal cytology.
56 See, for example, the flaws in RCTs of breast cancer screening identified by Gotzsche PC, Nielsen M. Screening for breast cancer with mammography. *Cochrane Database of Systematic Reviews*. 2009.


77 Cuzick J, Clavel C, Petry KU et al. Overview of the European and North American studies on HPV
78 Reelick NF, de Haes WF and Schuurman JH. Psychological side-effects of the mass screening on
80 Gray NM, Sharp L, Cotton SC et al. Psychological effects of a low-grade abnormal cervical smear test
81 Korfage IJ, van Ballegooijen M, Huveneers H et al. Anxiety and borderline PAP smear results. *European
82 Heinonen A, Tapper A-M, Leminen A et al. Health-related quality of life and perception of anxiety in
women with abnormal cervical cytology referred for colposcopy: an observational study. *European
83 Sharp L, Cotton S, Carsin AE et al. Factors associated with psychological distress following colposcopy
among women with low-grade abnormal cervical cytology: a prospective study within the Trial Of
Management of Borderline and Other Low-grade Abnormal smears (TOMBOLA). *Psycho-Oncology*. 2013;
22(2): 368-80.
85 Korfage IJ, van Ballegooijen M, Huveneers H et al. Anxiety and borderline PAP smear results. *European
86 Hellsten C, Sjöström K and Lindqvist P. A longitudinal 2-year follow-up of quality of life in women
referred for colposcopy after an abnormal cervical smear. *European Journal of Obstetrics & Gynecology
and Reproductive Biology*. 2009; 147(2): 221-5.
87 Korfage IJ, Essink-Bot M-L, Westenberg SM et al. How distressing is referral to colposcopy in cervical
88 Bell S, Porter H, Kitchener H et al. Psychological response to cervical cancer screening *Preventive
89 Gray NM, Sharp L, Cotton SC et al. Psychological effects of a low-grade abnormal cervical smear test
90 Korfage IJ, van Ballegooijen M, Huveneers H et al. Anxiety and borderline PAP smear results. *European
92 Hellsten C, Lindqvist P and Sjöström K. A longitudinal study of sexual functioning in women referred
115(2): 205-11.
93 French DP, Maissi E and Marteau TM. Psychological costs of inadequate cervical smear test results.
94 Wilkinson C, Jones JM and McBride J. Anxiety caused by abnormal result of cervical smear test: a
95 Gibb RK and Martens MG. The impact of liquid-based cytology in decreasing the incidence of cervical
97 Ibid.
98 Arbyn M, Bergeron C, Klinkhamer P et al. Liquid compared with conventional cervical cytology: a


The denominator is based on a screening rate of 70% for the 1,151,500 women ages 30-64 in B.C. in 2015.


Personal communication with Dr. Andy Coldman, Vice President, Population Oncology, BC Cancer Agency, February 10, 2012. Chart based on data from the B.C. Cancer Registry.


In this study, the age at onset was determined as follows: “the age at which the incidence rate starts to increase markedly (onset), defined as the age at which a straight line (fitted to the segment between 10 and 40% of the increase from zero to peak) intersects the age axis.”


Ibid.


Ibid.


Ibid.
258 Sasieni P, Castanon A and Cuzick J. Effectiveness of cervical screening with age: population based case-control study of prospectively recorded data. BMJ. 2009; 339:
264 Ibid
270 Ibid.

Einstein MH. Women whose cervical intraepithelial neoplasia has been treated or resolved remain at continued high risk for cervical cancer. *Evidence Based Medicine*. 2013; 18(5): 190-1.


In the 2001 Bethesda system, BMD corresponds to atypical squamous cells of undetermined significance, atypical squamous cells, cannot exclude high-grade squamous intraepithelial lesions, or low-grade squamous intraepithelial lesions.

In the 2001 Bethesda system, >BMD corresponds to high-grade squamous or glandular intraepithelial lesions.


362 Ibid